Skip to main content
main-content

Arrhythmia

Latest articles

01-03-2017 | Arrhythmia | News | Article

No reduction in AF recurrence with aggressive blood pressure treatment

Reducing target blood pressure does not decrease the incidence of recurrent arrhythmia among patients undergoing catheter ablation for atrial fibrillation, results of a randomized trial suggest.

Source:

Circulation 2017; Advance online publication

16-02-2017 | Arrhythmia | Main feed | Article

Real-world effectiveness, safety of novel oral anticoagulants in AF explored

A Danish nationwide cohort study published in The BMJ examines the effectiveness and safety profiles of novel oral anticoagulants among patients with atrial fibrillation.

Source:

BMJ 2017; 356: j510

06-12-2016 | Thrombosis | News | Article

Editor's pick

Oral thrombin inhibitor treatment could increase blood clot formation

The oral thrombin inhibitor dabigatran may actually increase thrombus formation, suggest the results of a translational study conducted in human arterial plaque and mouse models of blood clotting.

Source:

Sci Transl Med 2016; 8: 367ra168

15-11-2016 | Interventional cardiology | News | Article

Rivaroxaban reduces bleeding risk after PCI in patients with atrial fibrillation

Use of rivaroxaban moderates the bleeding risk associated with oral anticoagulation plus antiplatelet treatment after percutaneous coronary intervention in patients with atrial fibrillation, indicate results of the phase III PIONEER AF-PCI trial.

Source:

N Engl J Med 2016; Advance online publication; AHA 2016, Louisiana, USA

07-09-2016 | Arrhythmia | News | Article

More focus needed on non-stroke events in AF

Atrial fibrillation is associated with an increased risk of a wide range of adverse outcomes including death and cardiovascular and renal disease, results of a systematic review and meta-analysis involving more than 9 million individuals show.

Source:

BMJ 2016; 354: i4482

05-09-2016 | Arrhythmia | News | Article

Edoxaban ENSUREs effective cardioversion in non-valvular atrial fibrillation

Edoxaban appears to be an effective alternative to warfarin and enoxaparin bridging for cardioversion of patients with non-valvular atrial fibrillation, findings from a phase IIIb trial show.

Source:

Lancet 2016; Advance online publication

26-08-2016 | Arrhythmia | News | Article

Women at greater risk of post-ablation VT recurrence

Women are more likely than men to have recurrent ventricular tachycardia following ablation, despite having more favourable baseline characteristics, research shows.

Source:

JAMA Cardiol 2016; Advance online publication

25-08-2016 | Arrhythmia | News | Article

Sudden cardiac death prediction model developed for general population

Researchers have developed and validated a risk model for predicting sudden cardiac death in adults without a history of cardiovascular disease.

Source:

Circulation 2016; Advance online publication

24-08-2016 | Arrhythmia | News | Article

AF linked to increased post-PCI complications

A history of atrial fibrillation is associated with an increased risk of in-hospital bleeding, heart failure, cardiogenic shock and mortality among patients undergoing percutaneous coronary intervention, US study data show.

Source:

J Am Coll Cardiol 2016; 68: 895–904 

23-08-2016 | Arrhythmia | News | Article

Cardiovascular risk factors prevalent many years before AF diagnosis

Cardiovascular risk factors can be present in patients with atrial fibrillation more than 15 years before an AF diagnosis, with each having its own trajectory, US researchers report.

Source:

Circulation 2016; 134: 599–610

16-08-2016 | Cardiology | News | Article

Editor's pick

Global variations in AF complications substantial

Rates of stroke, heart failure and death vary significantly by global region in patients presenting to emergency departments with atrial fibrillation, study findings indicate.

Source:

Lancet 2016; Advance online publication

11-08-2016 | Cardiology | News | Article

Brugada syndrome becoming less severe

The clinical presentation of the inherited cardiac arrhythmic disorder Brugada syndrome has become milder in the past 30 years, study findings indicate.

Source:

J Am Coll Cardiol 2016; 68: 614–623

10-08-2016 | Cardiology | News | Article

Stable INR values short-lived for majority of warfarin users

Only one-third of patients who achieve a stable international normalised ratio during 6 months of warfarin therapy will maintain that stability during the subsequent year’s treatment, US researchers report.

Source:

JAMA 2016; 316: 661–663

08-08-2016 | Arrhythmia | News | Article

Parenteral anticoagulation may not benefit AF patients with sepsis

The risk–benefit balance of parenteral anticoagulation may not be favourable in patients with atrial fibrillation who are hospitalised with sepsis, a study suggests.

Source:

JAMA Cardiol 2016; Advance online publication

28-07-2016 | Arrhythmia | News | Article

Apixaban 5 mg ‘appropriate’ in AF patients with one dose-reduction criterion

The benefits of apixaban 5 mg over warfarin are maintained in patients with atrial fibrillation who are of advanced age, have low body weight or elevated creatinine levels, analysis of ARISTOTLE data shows.

Source:

JAMA Cardiol 2016; Advance online publication

07-07-2016 | Arrhythmia | News | Article

Secondary outcomes favour cryoballoon ablation in paroxysmal AF

Reintervention and rehospitalisation rates are significantly lower with cryoballoon ablation than with radiofrequency current catheter ablation in patients with symptomatic paroxysmal atrial fibrillation, FIRE AND ICE study data show.

Source:

Eur Heart J 2016; Advance online publication

06-07-2016 | Arrhythmia | News | Article

Real-world study backs anticoagulation in very elderly

Very elderly patients given a vitamin K antagonist in clinical practice have a mildly elevated risk of bleeding but a sharply increased risk of thrombosis, say researchers.

Source:

JAMA Intern Med 2016; Advance online publication

01-07-2016 | Arrhythmia | News | Article

‘Comprehensive’ management approach needed for AF

Death is a bigger risk than stroke among patients with atrial fibrillation, particularly during the first 4 months after diagnosis, research shows.

Source:

Eur Heart J 2016; Advance online publication

28-06-2016 | Arrhythmia | News | Article

Pharmacotherapy reduces conduction system disease risk

Lisinopril therapy significantly reduces incident conduction system disease, indicates a post-hoc analysis of ALLHAT data.

Source:

JAMA Intern Med 2016; Advance online publication

24-06-2016 | Arrhythmia | News | Article

Race impacts adverse outcomes in atrial fibrillation

Black individuals with atrial fibrillation have markedly higher rates of stroke, heart failure, coronary heart disease and mortality than their White counterparts, data from the Atherosclerosis Risk in Communities study show.

Source:

JAMA Cardiol 2016; Advance online publication

image credits